SECOND REGULAR SESSION
94TH GENERAL ASSEMBLY
INTRODUCED BY REPRESENTATIVES HUBBARD (Sponsor), CHAPPELLE-NADAL, EL-AMIN AND NASHEED (Co-sponsors).
Read 1st time April 1, 2008 and copies ordered printed.
D. ADAM CRUMBLISS, Chief Clerk
AN ACT
To amend chapter 191, RSMo, by adding thereto one new section relating to prostate cancer imaging technologies.
Be it enacted by the General Assembly of the state of Missouri, as follows:
Section A. Chapter 191, RSMo, is amended by adding thereto one new section, to be known as section 191.955, to read as follows:
191.955. 1. This section shall be known and may be cited as the "Prostate Research, Imaging, and Men's Education Act" or "PRIME Act".
2. The director of the department of health and senior services shall establish a program to expand and intensify research to develop innovative advanced imaging technologies for prostate cancer detection, diagnosis, and treatment comparable to state-of-the-art mammography technologies.
3. (1) The director shall implement a statewide campaign to increase the awareness and knowledge of Missourians with respect to the need for prostate cancer screening and for improved detection technologies.
(2) The statewide campaign shall include the development and distribution of written educational materials, and the development and placing of public service announcements that are intended to encourage men to seek prostate cancer screening and to create awareness of the need for improved imaging technologies for prostate cancer detection and minimally invasive treatment.
(3) In developing the statewide campaign, the director shall recognize and address the racial disparities in the incidences of prostate cancer and mortality rates with respect to such disease.
(4) The director shall establish a program to award grants to nonprofit entities to enable such entities to test alternative outreach and education strategies to increase the awareness and knowledge of Missourians with respect to the need for prostate cancer screening and improved imaging technologies.
4. The director shall carry out research to develop an improved prostate cancer screening blood test using in-vitro detection.
5. (1) Not later than six months after the effective date of this section, the director shall submit a report to the general assembly that details the strategy of the director for implementing the requirements of this section and the status of such efforts.
(2) Not later than one year after the effective date of this section, and annually thereafter, the director shall submit a report to the general assembly that:
(a) Contains assurances that the provisions of this section are fully implemented; and
(b) Certifies such compliance, or in the case of a failure to comply, an explanation as to such failure to comply.
•